Dellas, Claudia

[["dc.bibliographiccitation.firstpage","2716"],["dc.bibliographiccitation.issue","24"],["dc.bibliographiccitation.journal","Circulation"],["dc.bibliographiccitation.lastpage","U300"],["dc.bibliographiccitation.volume","124"],["dc.contributor.author","Lankeit, Mareike"],["dc.contributor.author","Jimenez, David"],["dc.contributor.author","Kostrubiec, Maciej"],["dc.contributor.author","Dellas, Claudia"],["dc.contributor.author","Hasenfuß, Gerd"],["dc.contributor.author","Pruszczyk, Piotr"],["dc.contributor.author","Konstantinides, Stavros"],["dc.date.accessioned","2017-09-07T11:43:13Z"],["dc.date.available","2017-09-07T11:43:13Z"],["dc.date.issued","2011"],["dc.description.abstract","Background-The new, high-sensitivity troponin T (hsTnT) assay may improve risk stratification of normotensive patients with acute pulmonary embolism (PE). We externally validated the prognostic value of hsTnT, and of the simplified Pulmonary Embolism Severity Index (sPESI), in a large multicenter cohort. Methods and Results-We prospectively examined 526 normotensive patients with acute PE; of those, 31 (5.9%) had an adverse 30-day outcome. The predefined hsTnT cutoff value of 14 pg/mL was associated with a high prognostic sensitivity and negative predictive value, comparable to those of the sPESI. Both hsTnT >= 14 pg/mL (OR, 4.97 [95% CI, 1.71-14.43]; P=0.003) and sPESI >= 1 point(s) (OR, 9.51 [2.24-40.29]; P=0.002) emerged, besides renal insufficiency (OR, 2.97 [1.42-6.22]; P=0.004), as predictors of early death or complications; in a multivariable model, they remained independent predictors of outcome (P=0.044 and 0.012, respectively). A total of 127 patients (24.1%) were identified as low risk by a sPESI of 0 and hsTnT >= 14 pg/mL; none of them had an adverse 30-day outcome. During 6-month follow-up, 52 patients (9.9%) died. Kaplan-Meier analysis illustrated that patients with hsTnT >= 14 pg/mL (P=0.001) and those with sPESI >= 1 (P=0.001) had a decreased probability of 6-month survival. Patients with sPESI of 0 and hsTnT >= 14 pg/mL at baseline had a 42% reduction in the risk of dying (hazard ratio, 0.58 [0.01-0.42]; P=0.005). Conclusions-The hsTnT assay and the sPESI improve risk stratification of acute PE. Combination of both modalities may yield additive prognostic information and particularly identify possible candidates for out-of-hospital treatment. (Circulation. 2011;124:2716-2724.)"],["dc.identifier.doi","10.1161/CIRCULATIONAHA.111.051177"],["dc.identifier.gro","3142615"],["dc.identifier.isi","000298351600021"],["dc.identifier.pmid","22082681"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/7821"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/39"],["dc.notes.intern","WoS Import 2017-03-10"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","final"],["dc.notes.submitter","PUB_WoS_Import"],["dc.publisher","Lippincott Williams & Wilkins"],["dc.relation.issn","0009-7322"],["dc.rights","Goescholar"],["dc.rights.uri","https://goescholar.uni-goettingen.de/licenses"],["dc.title","Predictive Value of the High-Sensitivity Troponin T Assay and the Simplified Pulmonary Embolism Severity Index in Hemodynamically Stable Patients With Acute Pulmonary Embolism A Prospective Validation Study"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.subtype","original"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","509"],["dc.bibliographiccitation.issue","8"],["dc.bibliographiccitation.journal","Clinical Research in Cardiology"],["dc.bibliographiccitation.lastpage","511"],["dc.bibliographiccitation.volume","98"],["dc.contributor.author","Dellas, Claudia"],["dc.contributor.author","Chapuy, Bjoern"],["dc.contributor.author","Schweyer, Stefan"],["dc.contributor.author","Hasenfuß, Gerd"],["dc.contributor.author","Huenlich, Mark"],["dc.date.accessioned","2017-09-07T11:46:53Z"],["dc.date.available","2017-09-07T11:46:53Z"],["dc.date.issued","2009"],["dc.identifier.doi","10.1007/s00392-009-0034-0"],["dc.identifier.gro","3143081"],["dc.identifier.isi","000268511200006"],["dc.identifier.pmid","19499163"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/5027"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/555"],["dc.notes.intern","WoS Import 2017-03-10"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","final"],["dc.notes.submitter","PUB_WoS_Import"],["dc.publisher","Dr Dietrich Steinkopff Verlag"],["dc.relation.issn","1861-0684"],["dc.rights","Goescholar"],["dc.rights.uri","https://goescholar.uni-goettingen.de/licenses"],["dc.title","A rare cause of sudden cardiac arrest: primary cardiac lymphoma"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.subtype","letter_note"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","2150"],["dc.bibliographiccitation.issue","19"],["dc.bibliographiccitation.journal","Journal of the American College of Cardiology"],["dc.bibliographiccitation.lastpage","2157"],["dc.bibliographiccitation.volume","55"],["dc.contributor.author","Dellas, Claudia"],["dc.contributor.author","Puls, Miriam"],["dc.contributor.author","Lankeit, Mareike"],["dc.contributor.author","Schaefer, Katrin"],["dc.contributor.author","Cuny, Mayumi"],["dc.contributor.author","Berner, Maik"],["dc.contributor.author","Hasenfuß, Gerd"],["dc.contributor.author","Konstantinides, Stavros"],["dc.date.accessioned","2017-09-07T11:46:04Z"],["dc.date.available","2017-09-07T11:46:04Z"],["dc.date.issued","2010"],["dc.description.abstract","Objectives We assessed the predictive value of heart-type fatty acid-binding protein (H-FABP) in normotensive patients with acute pulmonary embolism (PE). Background Risk stratification of initially normotensive patients with PE on the basis of right ventricular dysfunction or injury remains controversial. Previous studies investigating biomarkers or imaging modalities included unselected patients, some of whom presented with cardiogenic shock. Methods We included 126 consecutive normotensive patients with confirmed PE. Complicated 30-day outcome was defined as death, resuscitation, intubation, or use of catecholamines. Long-term survival was assessed by follow-up clinical examination. Results During the first 30 days, 9 (7%) patients suffered complications. These patients had higher baseline H-FABP values (median, 11.2 ng/ml [interquartile range: 8.0 to 36.8 ng/ml]) compared with patients with an uncomplicated course (3.4 ng/ml [2.1 to 4.9 ng/ml]; p < 0.001). H-FABP values were above the calculated (by receiver operating characteristic curve analysis) cutoff value of 6 ng/ml in 29 patients. Eight (28%) of them suffered complications versus 1 of 97 patients with low H-FABP (negative predictive value, 99%; p < 0.001). By logistic regression, elevated (>= 6 ng/ml) H-FABP was associated with a 36.6-fold increase in the death or complication risk. The combination of H-FABP with tachycardia was a particularly useful prognostic indicator. H-FABP also predicted long-term mortality over 499 (interquartile range: 204 to 1,166) days (hazard ratio: 3.6; 95% confidence interval: 1.6 to 8.2; p = 0.003). Conclusions The H-FABP might be a useful biomarker for risk stratification of normotensive patients with acute PE. (J Am Coll Cardiol 2010;55:2150-7) (C) 2010 by the American College of Cardiology Foundation"],["dc.identifier.doi","10.1016/j.jacc.2009.10.078"],["dc.identifier.gro","3142925"],["dc.identifier.isi","000277303100019"],["dc.identifier.pmid","20447541"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/6377"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/383"],["dc.notes.intern","WoS Import 2017-03-10 / Funder: University of Goettingen"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","final"],["dc.notes.submitter","PUB_WoS_Import"],["dc.publisher","Elsevier Science Inc"],["dc.relation.issn","0735-1097"],["dc.rights","Goescholar"],["dc.rights.uri","https://goescholar.uni-goettingen.de/licenses"],["dc.title","Elevated Heart-Type Fatty Acid-Binding Protein Levels on Admission Predict an Adverse Outcome in Normotensive Patients With Acute Pulmonary Embolism"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.subtype","original"],["dc.type.version","submitted_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.journal","Clinical Research in Cardiology"],["dc.contributor.author","Barco, Stefano"],["dc.contributor.author","Russo, Mariaconcetta"],["dc.contributor.author","Vicaut, Eric"],["dc.contributor.author","Becattini, Cecilia"],["dc.contributor.author","Bertoletti, Laurent"],["dc.contributor.author","Beyer-Westendorf, Jan"],["dc.contributor.author","Bouvaist, Hélène"],["dc.contributor.author","Couturaud, Francis"],["dc.contributor.author","Danays, Thierry"],["dc.contributor.author","Dellas, Claudia"],["dc.contributor.author","Duerschmied, Daniel"],["dc.contributor.author","Empen, Klaus"],["dc.contributor.author","Ferrari, Emile"],["dc.contributor.author","Galiè, Nazzareno"],["dc.contributor.author","Jiménez, David"],["dc.contributor.author","Klok, Frederikus A."],["dc.contributor.author","Kostrubiec, Maciej"],["dc.contributor.author","Kozak, Matija"],["dc.contributor.author","Kupatt, Christian"],["dc.contributor.author","Lang, Irene M."],["dc.contributor.author","Lankeit, Mareike"],["dc.contributor.author","Meneveau, Nicolas"],["dc.contributor.author","Palazzini, Massimiliano"],["dc.contributor.author","Pruszczyk, Piotr"],["dc.contributor.author","Rugolotto, Matteo"],["dc.contributor.author","Salvi, Aldo"],["dc.contributor.author","Sanchez, Olivier"],["dc.contributor.author","Schellong, Sebastian"],["dc.contributor.author","Sobkowicz, Bozena"],["dc.contributor.author","Meyer, Guy"],["dc.contributor.author","Konstantinides, Stavros V."],["dc.date.accessioned","2019-07-09T11:51:00Z"],["dc.date.available","2019-07-09T11:51:00Z"],["dc.date.issued","2018"],["dc.description.abstract","INTRODUCTION: Symptoms and functional limitation are frequently reported by survivors of acute pulmonary embolism (PE). However, current guidelines provide no specific recommendations on which patients should be followed after acute PE, when follow-up should be performed, and which tests it should include. Definition and classification of late PE sequelae are evolving, and their predictors remain to be determined. METHODS: In a post hoc analysis of the Pulmonary Embolism Thrombolysis (PEITHO) trial, we focused on 219 survivors of acute intermediate-risk PE with clinical and echocardiographic follow-up 6 months after randomisation as well as over the long term (median, 3 years after acute PE). The primary outcome was a composite of (1) confirmed chronic thromboembolic pulmonary hypertension (CTEPH) or (2) 'post-PE impairment' (PPEI), defined by echocardiographic findings indicating an intermediate or high probability of pulmonary hypertension along with New York Heart Association functional class II-IV. RESULTS: Confirmed CTEPH or PPEI occurred in 29 (13.2%) patients, (6 with CTEPH and 23 with PPEI). A history of chronic heart failure at baseline and incomplete or absent recovery of echocardiographic parameters at 6 months predicted CTEPH or PPEI at long-term follow-up. CONCLUSIONS: CTEPH or PPEI occurs in almost one out of seven patients after acute intermediate-risk PE. Six-month echocardiographic follow-up may be useful for timely detection of late sequelae."],["dc.identifier.doi","10.1007/s00392-018-1405-1"],["dc.identifier.pmid","30564950"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/16028"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/59856"],["dc.language.iso","en"],["dc.notes.intern","Merged from goescholar"],["dc.relation.issn","1861-0692"],["dc.rights","CC BY 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by/4.0"],["dc.subject.ddc","610"],["dc.title","Incomplete echocardiographic recovery at 6 months predicts long-term sequelae after intermediate-risk pulmonary embolism. A post-hoc analysis of the Pulmonary Embolism Thrombolysis (PEITHO) trial"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","73"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","Clinical Research in Cardiology"],["dc.bibliographiccitation.lastpage","80"],["dc.bibliographiccitation.volume","102"],["dc.contributor.author","Lankeit, Mareike"],["dc.contributor.author","Friesen, Dietrich"],["dc.contributor.author","Schaefer, Katrin"],["dc.contributor.author","Hasenfuß, Gerd"],["dc.contributor.author","Konstantinides, Stavros"],["dc.contributor.author","Dellas, Claudia"],["dc.date.accessioned","2017-09-07T11:48:19Z"],["dc.date.available","2017-09-07T11:48:19Z"],["dc.date.issued","2013"],["dc.description.abstract","We tested whether bedside testing for H-FABP is, alone or integrated in combination models, useful for rapid risk stratification of non-high-risk PE. We prospectively studied 136 normotensive patients with confirmed PE. H-FABP was determined using a qualitative bedside-test showing a positive result for plasma concentration > 7 ng/ml. Overall, 11 patients (8.1 %) had an adverse 30-day outcome. Of 58 patients (42.6 %) with a positive H-FABP bedside-test, 9 (15.5 %) had an unfavourable course compared to 2 of 78 patients (2.6 %) with a negative test result (p = 0.009). Logistic regression analysis indicated a sevenfold increased risk for an adverse outcome (95 % CI, 1.45-33.67; p = 0.016) for patients with a positive H-FABP bedside-test. Additive prognostic information were obtained by a novel score including the H-FABP bedside-test (1.5 points), tachycardia (2 points), and syncope (1.5 points) (OR 11.57 [2.38-56.24]; p = 0.002 for >= 3 points). Increasing points were associated with a continuous exponential increase in the rate of an adverse 30-day outcome (0 % for patients with 0 points and 44.4 % for >= 5 points). Notably, this simple score provided similar prognostic value as the combination of the H-FABP bedside-test with echocardiographic signs of right ventricular dysfunction (OR 12.73 [2.51-64.43]; p = 0.002). Bedside testing for H-FABP appears a useful tool for immediate risk stratification of non-high-risk patients with acute PE, who may be at increased risk of an adverse outcome, in particular if integrated in a novel score without the need of echocardiographic examination."],["dc.identifier.doi","10.1007/s00392-012-0498-1"],["dc.identifier.gro","3142419"],["dc.identifier.isi","000313070900008"],["dc.identifier.pmid","23011575"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/8807"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/8074"],["dc.notes.intern","WoS Import 2017-03-10 / Funder: University of Gottingen (Heidenreich von Siebold Programme)"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","final"],["dc.notes.submitter","PUB_WoS_Import"],["dc.publisher","Springer"],["dc.publisher.place","Heidelberg"],["dc.relation.issn","1861-0684"],["dc.rights","Goescholar"],["dc.rights.uri","https://goescholar.uni-goettingen.de/licenses"],["dc.title","A simple score for rapid risk assessment of non-high-risk pulmonary embolism"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.subtype","original"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","1123"],["dc.bibliographiccitation.issue","6"],["dc.bibliographiccitation.journal","Thrombosis and Haemostasis"],["dc.bibliographiccitation.lastpage","1129"],["dc.bibliographiccitation.volume","100"],["dc.contributor.author","Dellas, Claudia"],["dc.contributor.author","Schaefer, Katrin"],["dc.contributor.author","Rohm, Ilonka"],["dc.contributor.author","Lankeit, Mareike"],["dc.contributor.author","Ellrott, Thomas"],["dc.contributor.author","Faustin, Vivien"],["dc.contributor.author","Riggert, Joachim"],["dc.contributor.author","Hasenfuß, Gerd"],["dc.contributor.author","Konstantinides, Stavros"],["dc.date.accessioned","2017-09-07T11:48:08Z"],["dc.date.available","2017-09-07T11:48:08Z"],["dc.date.issued","2008"],["dc.description.abstract","Clinical studies have shown that elevated leptin levels are an independent cardiovascular risk factor. However, little is known about the existence of platelet resistance to leptin in the setting of obesity. We examined the effects of leptin on platelet aggregation in morbidly obese subjects (n=40; BMI, 41.6 +/- 1.1 kg/m(2); leptin, 49.7 +/- 3.4 ng/ml) in comparison to normal-weight controls (n=36 BMI, 23.3 +/- 0.4 kg/m(2); leptin, 6.5 +/- 0.7 ng/ml).The aggregatory response to increasing concentrations of adenosine diphosphate (ADP) (2, 3,4,and 5 mu M) was significantly increased in platelets from obese compared to lean donors, reflecting a left shift in the dose-response curve. Plasma leptin levels, but not BMI, were significantly higher in subjects with stronger (above the median) compared to weaker (below the median) platelet aggregation at all ADP concentrations tested. In further experiments, stimulation (preincubation) with leptin (500 ng/ml) promotedADP-induced platelet aggregation by approximately 25%, and there was no difference between platelets from obese and those from lean donors regarding the responsiveness to leptin (p=0.99). Western blotting revealed that leptin induced phosphorylation of JAK2 and STAT3 to a similar extent in platelets from both groups. Expression of potential mediators of leptin resistance (SOCS3 and PTP IB) also did not differ in platelets from obese and control subjects. In conclusion,our data indicate that platelets from obese donors show increased aggregatory response to ADP, and that this might partly be the consequence of increased circulating leptin levels. Platelets from obese donors are not resistant to the enhancing effects of leptin on ADP-induced platelet aggregation."],["dc.identifier.doi","10.1160/TH08-05-0314"],["dc.identifier.gro","3143206"],["dc.identifier.isi","000261880900030"],["dc.identifier.pmid","19132239"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/6290"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/695"],["dc.notes.intern","WoS Import 2017-03-10 / Funder: German Research Foundation; University of Goettingen"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","final"],["dc.notes.submitter","PUB_WoS_Import"],["dc.publisher","Schattauer Gmbh-verlag Medizin Naturwissenschaften"],["dc.relation.issn","0340-6245"],["dc.rights","Goescholar"],["dc.rights.uri","https://goescholar.uni-goettingen.de/licenses"],["dc.title","Absence of leptin resistance in platelets from morbidly obese individuals may contribute to the increased thrombosis risk in obesity"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.subtype","original"],["dspace.entity.type","Publication"]]